Viatris
Viatris makes generic and off-patent branded drugs, spun off from Pfizer's Upjohn and Mylan in 2020.
The call
Viatris runs a huge, cash-generating generics business that nobody truly owns, competing on cost against peers with the same tools while it cuts staff and chases a thin branded pipeline.
Viatris is a company that makes generic versions of medications whose patents have expired, selling them cheaply to hospitals and pharmacies. Anybody else can do exactly what Viatris does, because generic drugs do not have special protections: Teva, Sandoz, Sun Pharmaceuticals, and others have the same government approvals, the same ability to run factories, and the same store shelves to sell through. Viatris's sales are actually shrinking, it owns almost no brand-name drugs with patent protection, and it is laying off workers to cut costs. The one thing that could turn this around is if the company's new drugs in development, like meloxicam and selatogrel, actually make it to patients and earn real profits before their patents expire, though right now almost everything it sells is just cheap commodity.
Why
01
AI pressure: None apparent. AI drug discovery tools target novel molecules, not the off-patent copies Viatris sells, so this fight is elsewhere for now. Could AI do the core job? Unlikely.
02
Bigger players: Teva, Sandoz, Sun Pharmaceuticals, Aurobindo, Dr. Reddy's, Lupin. These rivals hold the same FDA approvals, the same GMP plants, and the same buyers, so they can undercut Viatris on nearly identical products. Could a giant copy it? Yes, easily.
03
What protects it. Scale in manufacturing and distribution plus $2.2B free cash flow let it hold price and pay down debt while smaller generic makers can't.
What would change this call
Q2 2026 earnings (Aug 6, 2026) show restructuring savings tracking toward $600-700M annual target. Confirms cost cuts are real and not just announced plans.
Indore, India FDA import alert lifted or extended before end of 2026. Shows whether the ~$500M revenue hit from supply disruption is resolving or worsening.
Meloxicam NDA decision or selatogrel/sonarimod trial data released in 2026-2027. Indicates whether Viatris can add any branded-margin products beyond its ~1% patent-protected base.
Indore, India FDA import alert lifted or extended before end of 2026. Shows whether the ~$500M revenue hit from supply disruption is resolving or worsening.
Meloxicam NDA decision or selatogrel/sonarimod trial data released in 2026-2027. Indicates whether Viatris can add any branded-margin products beyond its ~1% patent-protected base.
Key numbers
- FY2025 revenue $14.3B, down 3% YoY
- Only ~1% of portfolio still patent-protected
- Indore plant issue cost ~$500M in 2025 revenue
Named risks
- Restructuring execution risk: 10% workforce cut and $700-850M charges must deliver promised $600-700M savings over three years.
- Manufacturing/quality issues, including Indore India import alert and plant fire, costing ~$500M in 2025 revenue.
- Ongoing litigation overhang: EpiPen antitrust settlements and valsartan contamination MDL with ~1,418 active lawsuits as of July 2026.
- Leadership transition risk following CFO Theodora Mistras departure announced May 4, 2026, during active restructuring.
- Revenue decline (~3% YoY in FY2025) with 99% of portfolio off-patent, exposed to commodity pricing pressure from identically-equipped generics peers.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Teva Pharmaceuticals | contesting | Cited as leading generics rival alongside Viatris in generic drug market reports, June 2026 |
| Sandoz | gaining on | Spun off from Novartis in 2023 with strong biosimilars growth cited as competitive pressure, per 2025-2026 industry coverage |
| Sun Pharmaceuticals | contesting | Named as a peer generics competitor in June 2026 market analysis |
| Aurobindo Pharma | contesting | Listed among equally-equipped commodity generics peers competing for same ANDA-based volume |
| Dr. Reddy's Laboratories | contesting | Named as generics peer with overlapping regulatory approvals and manufacturing capacity |
| Lupin Pharmaceuticals | contesting | Cited alongside Viatris in generics market forecast reports covering 2025-2033 |
Questions people ask
- Is Viatris profitable in 2026?
- Yes on a cash basis: Viatris reported Q1 2026 GAAP net earnings of $176 million and generated about $2.2 billion in free cash flow for full-year 2025, though total FY2025 revenue fell about 3% to $14.3 billion versus 2024's $14.7 billion (as of Feb 26, 2026).
- Is Viatris doing layoffs?
- Yes. On February 26, 2026, Viatris announced plans to cut its global workforce by about 10% over three years, with $700-850 million in pre-tax restructuring charges, including winding down its Damastown, Dublin plant by 2028 affecting up to 340 jobs.
- Could AI replace Viatris?
- Not directly. Viatris relies on FDA-approved ANDA/NDA filings, GMP-certified physical manufacturing plants, and established wholesaler/PBM distribution relationships, none of which AI can substitute; no evidence as of 2026 shows Viatris citing AI as a driver of its 10% workforce cuts.
- Who is Viatris's biggest competitor?
- Viatris competes directly with Teva Pharmaceuticals, Sandoz, Sun Pharmaceuticals, Aurobindo Pharma, Dr. Reddy's Laboratories, and Lupin in generics, all holding similar ANDA approvals and manufacturing capacity, per June 2026 industry coverage.
- Who owns Viatris?
- Viatris is an independent public company (Nasdaq: VTRS) with no controlling parent, formed by the 2020 merger of Pfizer's Upjohn unit with Mylan N.V.; its market cap was approximately $20.1 billion as of July 20, 2026.
- Why did Viatris stock drop or struggle in 2025-2026?
- Revenue declined about 3% in FY2025 to $14.3 billion partly due to a manufacturing/FDA import alert at its Indore, India facility that cost an estimated $500 million in 2025 revenue, plus ongoing EpiPen and valsartan litigation overhang.
Timeline
- 2026-07-14Mylan (Viatris unit) sells Biocon stake via block deal worth up to $363 million
- 2026-05-18FDA accepts New Drug Application for fast-acting meloxicam MR-107A-02
- 2026-05-07Viatris reports Q1 2026 revenue of $3.5 billion, up 8% reported YoY
- 2026-05-04CFO Theodora Doretta Mistras announces departure
- 2026-03-19Viatris holds Investor Event outlining post-restructuring strategy
- 2026-02-27Up to 340 jobs to be cut at Damastown, Dublin plant, winding down by 2028
- 2026-02-26Viatris announces 10% workforce cut over 3 years and discloses fire at India plant
- 2026-02-26FY2025 results: $14.3 billion revenue, down about 3% YoY
- 2026-02-13Indiana AG reaches $6.25 million EpiPen antitrust settlement with Viatris
- 2025-06-09Viatris discloses Indore, India import alert cost ~$500 million in 2025 revenue
Revision history
20 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results (2026-02-26)
- Viatris Reports First Quarter 2026 Financial Results (2026-05-07)
- Viatris to cut 10% of workforce in 3-year overhaul (2026-02-26)
- Viatris at Goldman Sachs Conference: Strategic Shifts and Challenges (2025-06-09)
- Up to 340 jobs to go at Viatris plant in Damastown, Co Dublin (2026-02-27)
- Viatris Number of Employees 2026 (2026-06-29)
- GuruFocus (2026-07-20)
- Viatris newsroom archive (2026-06-29)
- Biocon shares gain 6.5% after Viatris sells its stake in a block deal (2026-07-14)
- Indiana Reaches $6.25M EpiPen Settlement (2026-02-13)
- 2026 Lawsuit Updates & Cancer Claims (2026-07-01)